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The C3 receptors of most phagocytic cells promote avid binding of particles 
coated with C3 but do not promote their ingestion (1-10).  We have previously 
(7-12) described a  unique lymphokine that activates the C3 receptors of mouse 
peritoneal macrophages for phagocytosis. Generation of the lymphokine in vitro 
requires an unusual series of cellular interactions.  Macrophages must first phag- 
ocytize  IgG-containing  immune  complexes,  thereby  acquiring  the  ability  to 
trigger T  lymphocytes to elaborate the lymphokine (7). 
All of the elements required to generate the lymphokine--immune complexes, 
macrophages, and T  lymphocytes--are present at sites of immunologically me- 
diated inflammation in vivo. In the present experiments we created immunolog- 
ically mediated inflammation  at a site in vivo, harvested macrophages from the 
site,  and  assessed  their  C3  receptor  activity.  Our  findings  suggest  that  the 
lymphokine  we have generated  in  vitro is produced by similar  mechanisms  in 
vivo and that it may be a critical determinant of macrophages'  ability to phago- 
cytize opsonized microorganisms in vivo. 
Materials and Methods 
Reagents  and  Media.  Medium  199  (Microbiological  Associates,  Walkersville,  MD); 
bovine serum albumin  (BSA), trypsin,  lyophilized  human  serum albumin  (HSA),  and 
glycine  (Sigma  Chemical  Co.,  St.  Louis,  MO);  lyophilized  rabbit  anti-BSA  IgG  and 
lyophilized rabbit gamma globulin  (Cappel Laboratories, Cochranville,  PA); sheep eryth- 
rocytes (E)  (Scott  Laboratories,  Inc.,  Fiskeville,  RI);  chromerge,  glutaraldehyde,  and 
concentrated sulfuric acid (Fisher Scientific Co., Pittsburgh, PA); and poly-L-lysine (PLL) 
(Miles Laboratories, Inc., Elkhart,  IN) were obtained from the manufacturers indicated. 
Preparation of Immunologically  Coated E.  E coated with anti-E  IgG (EIgG), E coated 
with anti-E  IgM (EIgM), and EIgM coated with the first  four complement components 
(EIgMC) were prepared as previously described (3). 
Preparation of Soluble Immune Complexes and Aggregates.  Rabbit anti-HSA  antiserum 
was prepared by repeatedly immunizing a rabbit with HSA. It was heat-decomplemented 
(56°C for 30 rain) and incubated with  HSA to prepare soluble immune complexes as 
previously described (9). Aggregated IgG was prepared by heating rabbit gamma globulin 
at 63°C for 45 min, as previously described (9). 
Animals  and  Cells.  20-30-g  female  Swiss mice  (strain  CD-1)  were  obtained  from 
Charles  River Breeding Laboratories,  Inc.,  Wilmington,  MA; 20-30-g female athymic 
BALB/c mice and their female euthymic littermates  were obtained from Life Sciences, 
Inc., Greenwich,  CT. 
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Peritoneal cells were harvested by lavage from noninjected mice and from mice injected 
intraperitoneally 4 d  earlier with either 5 mg of aggregated IgG, HSA-anti-HSA com- 
plexes containing 5 mg of HSA, or a control preparation. Macrophages were purified by 
glass adherence and were cultivated in medium at a concentration of 4 x  10  `4 per coverslip 
on  13-mm diam,  PLL-coated glass  coverslips in  35-ram  petri  dishes  or  24-well  tissue 
culture clusters (Costar; Bellco Glass, Inc., Vineland, N  J). 
C5-deficient mouse serum was obtained from 20-30-g female, C5-deficient AKR mice 
(The Jackson  Laboratory, Bar Harbor,  ME). It was adsorbed twice  at 4°C for  15 rain 
with 20% sheep E before being frozen in small aliquots at -70°C, and was thawed on ice 
just before use as a complement source. 
Preparation of Immobilized Immune Complexes.  Immobilized immune complexes were 
fixed onto 13-mm glass coverslips as previously described (11, 13). 
Preparation of Lymphokine.  Culture supernatants containing the lymphokine that acti- 
vates mouse peritoneal macrophages' C3 receptors for phagocytosis were prepared and 
used as previously described (7). 
Assessment of Phagocytosis via Macrophages' C3 Receptors and Fc Receptors.  After a  1 h 
incubation,  macrophage  monolayers  were  washed,  overlaid  with  fresh  medium,  and 
incubated for an additional 3 h at 37 ° C. Some cells were then overlaid with lymphokine- 
containing supernatant,  others with fresh medium. 0.2 ml of 0.5%  E,  EIgG, EIgM, or 
EIgMC were added to each 35-mm petri dish, and cultures were incubated for 30 min at 
37°C. Cultures were then washed and fixed with glutaraidehyde, and E attachment and 
ingestion  were scored by phase  contrast  microscopy. Because  in  all  of these assays all 
macrophages avidly  bound  EIgMC and  none  bound  or  ingested  either  E  or  EIgM, 
individual attachment and ingestion data obtained using these particles are not reported. 
Assessment of Macrophage C3 Receptor Mobility.  Freshly harvested macrophages were 
plated on coverslips coated with C3-containing immune complexes. After a 1 h incubation 
to allow macrophages to adhere, coverslips were washed and were overlaid with lympho- 
kine-containing supernatant or fresh medium. After a 15 min incubation at 37 ° C, cultures 
were washed and covered with 1 ml of fresh medium. 0.1  ml of 0.5% EIgMC was added 
to  each  well  and  cultures  were  incubated  for  1  h  at  37°C,  washed,  and  fixed  with 
glutaraldehyde. E attachment was scored by phase contrast microscopy. 
In this assay, C3 receptors that are mobile become trapped on the immobilized immune 
complexes when they diffuse randomly from the nonadherent to the adherent macrophage 
surface; rnacrophages with mobile receptors therefore lose the ability to bind EIgMC. In 
contrast,  C3  receptors that are immobile are unable to diffuse within the  macrophage 
plasma membrane and remain in place even when macrophages are plated on immobilized 
immune complexes; these macrophages therefore retain the ability to bind EIgMC. 
Presentation of  Results.  Unless otherwise indicated, each result presented is the average 
of at least  three separate determinations, each performed in duplicate.  The attachment 
index  and  the  phagocytic index  are  the  number  of E  attached  or  ingested  by  100 
macrophages and  were obtained  by multiplying the percent of macrophages that  had 
attached  or  ingested  any  E  by  the  average  number  of E  attached  or  ingested  per 
macrophage. Each result is presented as mean + SEM. 
Results 
Outbred Swiss mice were injected intraperitoneally with either soluble immune 
complexes or aggregated IgG. 4 d later, peritoneal macrophages were harvested, 
plated as  described  in  Materials  and  Methods,  and  assayed for their  ability to 
phagocytize via  their  Fc receptors and  C3  receptors.  Macrophages from  mice 
that had received no injection avidly ingested EIgG but failed to ingest EIgMC 
(Table  I,  line  1),  as  expected.  Macrophages  from  mice  injected  with  either 
nonaggregated lgG or "sham" immune complexes composed of HSA and non- 
immune rabbit serum behaved identically to those from mice that had received 
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TABLE  1 
Effects of ln Vivo Administration of Immune Complexes and 
Aggregates on the Fc Receptor and C3 Receptor Function of 
Macrophages from Euthymic and Athymic Mice 
Mice  Intraperitoneal  Phagocytic index 
injection  EIgG  EIgMC 
None  461 _+ 26  0 
Swiss  HSA-anti-HSA  47 +  3  79 -+ 9 
Aggregated lgG  89 -+ 10  91 -+ 24 
None  254*  0 
Euthymic [ittermates  HSA-anti-HSA  36*  138 -+ 13 
Aggregated lgG  43*  88 -+ 11 
None  465*  0 
Athymic  HSA-anti-HSA  113"  4  +  4 
Aggregated IgG  49*  6  -  3 
* Single determination. 
TABLE II 
Effect of Trypsin Treatment on Macrophage Fc Receptor Function 
Intraperitoneal injection 
Phagocytic index of EIgG by macrophages 
Nontreated  Trypsin-treated 
None  461 +  26  424 _+ 18 
HSA-anti-HSA  47 _+ 3  284 +  7 
Aggregated IgG  89 -+ 10  369 +  16 
been injected with either immune complexes or aggregates ingested EIgG poorly 
but were able to ingest EIgMC (Table I, lines 2 and 3). The defective uptake of 
EIgG by macrophages from mice that had received injections of immune com- 
plexes appeared to be due to blockade of the cells' Fc receptors by the complexes 
because treatment with 1 m g/ml of trypsin for 30 rain at 37 °C, a procedure that 
releases immune complexes from cells' Fc receptors (14), enabled macrophages 
to phagocytize EIgG efficiently (Table II). 
To  determine  whether  or  not  T  lymphocytes were  required  for  in  vivo 
activation of macrophages' C3 receptors, we performed experiments identical to 
those reported in  Table  I,  lines  1-3,  using athymic mice and their euthymic, 
congenic  littermates.  The  macrophages of the  euthymic littermates  behaved 
identically to those of outbred Swiss mice (Table I, lines 4-6); however, macro- 
phages from athymic mice were unable to phagocytize EIgMC (Table I, lines 7- 
9). Macrophages from athymic mice could, after immune complex uptake, signal 
T  lymphocytes from other mice to elaborate the lymphokine (data not shown), 
and these animals' macrophages could respond to the lymphokine in vitro (Table 
III), indicating that the failure of their C3 receptors to be activated in vivo was 
not due to an intrinsic defect in the macrophages' ability to participate in the 
generation of the lymphokine or in their ability to respond to it, but rather was 
due  to  the absence  of T  lymphocytes. Thus,  activation  of macrophages'  C3 
receptors in vivo requires T  lymphocytes. 
The C3 receptors of mouse peritoneal macrophages are normally immobilized 
and unable to diffuse within the cell's plasma membrane (11,  13). Activation of 
macrophages'  C3  receptors  for  phagocytosis  by  the  lymphokine  in  vitro  is 
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TABLE  III 
Response of Macrophages from Athymic Mice to Lymphokine 
Treatment In Vitro 
Phagocytic index of EIgMC 
Intraperitoneal injection 
Medium  Lymphokine 
None  0  92 --- 1 
HSA-anti-HSA  4 --. 4  110 +  6 
Aggregated IgG  6 +  3  101  -  6 
TABLE IV 
Effect of In Vivo Administration of Immune Complexes and 
Aggregates on Macrophages'  C3 Receptor Mobility 
Attachment index 
Mice  Intraperitoneal injection  of EIgMC 
None  1,224 --. 28 
Swiss  HSA-anti-HSA  108 -  16 
Aggregated IgG  115 ±  26 
None  1,074 --. 24 
Euthymic littermates  HSA-anti-HSA  83 +  16 
Aggregated lgG  83 --. 22 
None  692 ±  76 
Athymic  HSA-anti-HSA  795 ±  35 
Aggregated IgG  762 ±  68 
mobility accompanied in  vivo activation of macrophages' C3  receptors as well 
(Table IV).  C3  receptors of macrophages from all  mice were intrinsically im- 
mobile (Table IV, lines 1, 4, and 7) and unable to promote phagocytosis (Table 
I, lines 1, 4, and 7). C3 receptors of macrophages from euthymic mice that had 
received intraperitoneal  injections  of immune complexes or  aggregates  were 
both mobile (Table IV, lines 2,  3,  5, and 6) and able to promote phagocytosis 
(Table I, lines 2,  3,  5, and 6).  In contrast, C3  receptors of macrophages from 
athymic mice that had received injections of immune complexes or aggregates 
were both immobile (Table IV, lines 8 and 9) and unable to promote phagocytosis 
(Table I, lines 8 and 9). These results support our hypothesis that the lymphokine 
activates macrophages' C3  receptors for phagocytosis by freeing the receptors 
from their anchors and allowing them lateral mobility. 
Discussion 
In the present experiments we created an immunologicaily mediated inflam- 
matory focus in the mouse peritoneal cavity by injecting either soluble immune 
complexes  or  aggregated  IgG.  We  found  that  macrophages  present  at  this 
inflammatory site were markedly impaired in their ability to ingest via their Fc 
receptors but had acquired the ability to phagocytize via their C3 receptors. 
We have previously (9,  10)  found that  macrophages' Fc receptors could be 
blocked in  vitro by microgram quantities  of immune complexes. Our  finding 
that macrophages obtained from an in vivo milieu containing immune complexes 
were  defective  in  their  ability  to  phagocytize  IgG-coated  particles  strongly 
suggests that immune complexes can block the cells' Fc receptors in vivo as well. 
Receptor blockade was apparently achieved by occupancy of receptors by the 
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treatment promptly restored Fc receptor activity. The apparent ease with which 
macrophages' Fc receptors can be blocked by immune complexes in vivo strongly 
suggests that  these receptors may be  unable  to promote uptake of opsonized 
microorganisms at sites of infection in an immune host. 
Macrophages'  C3  receptors are  not  normally phagocytic (1-10).  We  have 
previously found (7-12) that a  unique lymphokine can activate these receptors 
so  that  they can  promote  phagocytosis.  For  T  lymphocytes to  elaborate  the 
lymphokine, they must receive a  signal  from macrophages that have  ingested 
IgG-containing immune complexes (7).  We therefore determined the ability to 
phagocytize via their C3 receptors of macrophages obtained from an inflamma- 
tory  focus containing macrophages,  immune complexes, and  T  lymphocytes. 
These macrophages were able to pbagocytize C3-coated particles, indicating that 
their  C3  receptors had  been activated in  vivo.  The  requirement for both  T 
lymphocytes  and immune complexes for activation of macrophages' C3 receptors 
in  vivo  is  identical  to  the  requirements  for  activation  of macrophages'  C3 
receptors in vitro, suggesting that the mechanisms we have identified for activa- 
tion of these receptors in vitro are the same mechanisms by which the receptors 
are activated for phagocytosis in vivo. 
Our  findings  support  the  following  model  for  the  ingestion  of opsonized 
microorganisms in vivo. Invading microorganisms become coated with both IgG 
and C3 in the immune host. Many pathogens shed antigens that become bound 
by host antibody, and soluble immune complexes composed of shed microbial 
antigen and host antibody are probably plentiful at sites of infection.  Macro- 
phages' Fc receptors are easily blocked when they ingest the immune complex 
debris,  thereby impairing these receptors' ability to clear IgG-coated microor- 
ganisms.  Uptake of these soluble complexes triggers macrophages to signal T 
lymphocytes to elaborate the lymphokine that activates macrophages' C3 recep- 
tors for phagocytosis. Unlike their Fc receptors, macrophages' C3 receptors are 
not very susceptible to blockade by immune complexes, even when the complexes 
contain  complement components  (9).  These  receptors  are  therefore able  to 
promote phagocytosis of the opsonized microorganisms.  Note that our model 
proposes  a  most  unusual  type of receptor cooperation  in  which  ingestion  of 
immune complex debris by macrophages' Fc receptors initiates a series of cellular 
and molecular events culminating in activation of the cells' C3 receptors and that 
it is the macrophages' C3 receptors, not their Fc receptors, that are primarily 
responsible for promoting phagocytosis of opsonized microorganisms. 
Summary 
We assessed the effects of exposure to immune complexes in vivo on macro- 
phages' Fc receptor function and C3 receptor function. Peritoneal macrophages 
from mice  injected intraperitoneally with  immune complexes were  markedly 
impaired in their ability to phagocytize via their Fc receptors but had acquired 
the ability to phagocytize via their C3  receptors.  In  vivo activation of macro- 
phages' C3 receptors for phagocytosis required T  lymphocytes, because macro- 
phages  from  athymic  mice  could  not  be  activated  by  injection  of  immune 
complexes. 
The requirement for both T  lymphocytes and immune complexes for activa- 
tion of macrophages' C3  receptors in vivo is identical to the requirements for 
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we  have  identified  for  activation  of  these  receptors  in  vitro  are  the  same 
mechanisms by which the receptors are activated for phagocytosis in vivo. The 
susceptibility of macrophages'  Fc receptors to blockade by immune complexes 
and the activation of their C3 receptors for phagocytosis in a  milieu containing 
immune complexes suggest that it may be macrophages' C3 receptors, not their 
Fc  receptors,  that  are  primarily  responsible  for  promoting  phagocytosis  of 
opsonized microorganisms in immune hosts. 
Received  for publication 3 April 1985. 
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